http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104906125-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate | 2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104906125-B |
| titleOfInvention | Application of microRNA 326 inhibitor in the medicine for preparing treatment cataract |
| abstract | The present invention relates to application of microRNA 326 inhibitor in the medicine for preparing treatment cataract.The present invention, which is experimentally confirmed microRNA 326, can suppress FGF1 expression, so as to lower the expression of betaB2 crystalline proteins, and the change of betaB2 crystalline protein contents is the key factor that cataract occurs, the downward of betaB2 crystalline protein expression quantity will cause cataract.Present invention prompting can treat cataract by suppressing microRNA 326, while microRNA 326 can be as the mark of Diagnosis of Cataract. |
| priorityDate | 2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.